• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Avalon GloboCare Corp. (Amendment)

    1/24/24 8:35:42 PM ET
    $AVCO
    Building operators
    Real Estate
    Get the next $AVCO alert in real time by email
    SC 13D/A 1 ea192098-13da3lu_avalon.htm AMENDMENT NO. 3 TO SCHEDULE 13D

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13D

    (Rule 13d-101)

    (Amendment No. 3)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    RULE 13d-2(a)

     

    AVALON GLOBOCARE CORP.

    (Name of Issuer)

     

    Common Stock, Par Value $.0001 Per Share

    (Title of Class of Securities)

     

    05344R 104

    (CUSIP Number)

     

    c/o Avalon Globocare Corp.

    4400 Route 9 South, Suite 3100, Freehold, New Jersey 07728

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    December 21, 2021

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box ☐.

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

     

     

     

     

     

    CUSIP No. 05344R 104

    13D

    Page 2 of 4 Pages

    1

     

    NAME OF REPORTING PERSONS

     

    Wenzhao Lu

     

    2 

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

      

    (a) ☐

    (b) ☐ 

    3

    SEC USE ONLY

     

     

    4

    SOURCE OF FUNDS*

     

    OO

     

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States  

     
             

    NUMBER OF

    7

     

    SOLE VOTING POWER

     

    3,733,788 (1)

    SHARES

    BENEFICIALLY

    OWNED BY

    8

     

    SHARED VOTING POWER 

     

    0 

    EACH
    REPORTING
    PERSON WITH

    9

     

    SOLE DISPOSITIVE POWER

     

    3,733,788 (1)

     

    10

     

    SHARED DISPOSITIVE POWER


    0 

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,733,788 (1)

     

    12

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

    ☐ 

    13

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    33.9% (2)

     

    14

     

    TYPE OF REPORTING PERSON (See Instructions)

     

    IN

     

     

    (1)As of the date hereof, Wenzhao Lu (the “Reporting Person”) may be deemed to beneficially own an aggregate of 3,733,788 shares of common stock, par value $0.0001 per share (the “Common Stock”) of Avalon Globocare Corp. (the “Issuer”), which amount includes 150,000 shares of Common Stock underlying a fully vested option which is exercisable within 60 days. This amount excludes additional shares of Common Stock of the Issuer that may be issuable upon conversion of 4,000 shares of the Issuer’s Series A Preferred Stock owned by the Reporting Person, which would have become convertible on November 9, 2023 but for a 4.99% beneficial ownership blocker provision set forth in the Certificate of Designation of the Issuer’s Series A Preferred Stock.

     

    (2) The foregoing reported beneficial ownership percentage is based on 10,999,534 shares of Common Stock of the Issuer issued and outstanding as of November 14, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on November 14, 2023. This amount reflects the one-for-ten reverse stock split of the Issuer, effective January 5, 2023, as reported by the Issuer in its Current Report on Form 8-K filed with the SEC on January 4, 2023.

     

     

     

    Item 1. Security and Issuer.

     

    This Schedule 13D relates to the Common Stock of the Issuer. The Issuer’s principal executive offices are located at Avalon Globocare Corp., 4400 Route 9 South, Suite 3100, Freehold, New Jersey 07728.

     

    Item 2. Identity and Background.

     

    This statement is being filed by and on behalf of the Reporting Person.

     

    The address of the principal office of the Reporting Person is c/o Avalon Globocare Corp., 4400 Route 9 South, Suite 3100, Freehold, New Jersey 07728.

     

    The Reporting Person is principally involved in the business of consulting and is the Chairman of the Board of Directors of the Issuer.

     

    The Reporting Person is a citizen of the United States.

     

    The Reporting Person is an accredited investor.

     

    During the last five years, the Reporting Person has not (i) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    Item 3. Source and Amount of Funds or Other Consideration.

     

    Funds for the purchase of the shares of Common Stock of the Issuer reported herein were from the Reporting Person’s personal funds. The Reporting Person paid approximately $7,308,823 to acquire 7,973,869 shares of Common Stock of the Issuer.

     

    Item 4. Purpose of Transaction.

     

    The Reporting Person has acquired the securities of the Issuer for investment purposes and such purchases have been made in the Reporting Person’s ordinary course of business.

     

    Item 5. Interest in Securities of the Issuer.

     

    As of the date hereof, the Reporting Person may be deemed to beneficially own 3,733,788 or 33.9% of the Common Stock of the Issuer, based on 10,999,534 shares of Common Stock issued and outstanding as of November 14, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the SEC on November 14, 2023. This amount reflects the one-for-ten reverse stock split of the Issuer, effective January 5, 2023, as reported by the Issuer in its Current Report on Form 8-K filed with the SEC on January 4, 2023.

     

    Except as described in this Schedule 13D, the Reporting Person has not effectuated any other transactions involving the securities of the Issuer in the last 60 days.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

     

    Other than as described in this Schedule 13D, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Person and any other person with respect to any securities of the Issuer.

     

    Item 7. Material to be Filed as Exhibits.

     

    None.

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and accurate.

     

    January 24, 2024 /s/ Wenzhao Lu
      Wenzhao Lu

     

     

     

     

     

    Get the next $AVCO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVCO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AVCO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avalon GloboCare Announces NASDAQ Ticker Symbol Change from "AVCO" to "ALBT"

      Company to Begin Trading under New Symbol "ALBT" on November 10, 2022 Symbol Change Better Reflects Avalon's New Focus on Laboratory Services and Biotherapeutics FREEHOLD, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced that its ticker symbol will change on the NASDAQ Stock Exchange from "AVCO" to "ALBT" at the open of market trading on Thursday, November 10, 2022. David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon, commented, "Yesterday we announced a transformative acquisition of Laboratory Services MSO, LLC,

      11/9/22 4:00:00 PM ET
      $AVCO
      Building operators
      Real Estate
    • Avalon GloboCare Signs Definitive Agreement for Transformational Acquisition of Leading Laboratory with 2021 Unaudited Revenue in Excess of $25 Million

      Company to acquire a majority interest in Laboratory Services MSO, LLC, a leading reference laboratory with 2021 unaudited revenue in excess of $25 million, net income in excess of $10 million and over 600,000 tests completed since inception Cash portion to be financed with a private placement of $15 million of Avalon preferred stock, convertible at a floor of $1.00 per share, with leak-out provisions, no warrants and a 9-month lock up Company to Begin Trading under New Symbol "ALBT" on November 10, 2022 FREEHOLD, N.J., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company")(NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and

      11/8/22 9:10:00 AM ET
      $AVCO
      Building operators
      Real Estate
    • Avalon Globocare to Present at the LD Micro Main Event XV on October 26th

      Freehold, New Jersey--(Newsfile Corp. - October 19, 2022) - Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Chief Financial Officer of Avalon GloboCare, will be presenting at the 15th annual LD Micro Main Event being held on October 25 - 27, 2022 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.Presentation details:Event:LD Micro Main Event XVDate:Wednesday, October 26th, 2022Time:4:00 PM PT/ 7:00 PM ET Register to watch the virtual presentation here.Management will be available for one-on-one meetings

      10/19/22 9:00:00 AM ET
      $AVCO
      Building operators
      Real Estate

    $AVCO
    SEC Filings

    See more
    • Avalon GloboCare Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Avalon GloboCare Corp. (0001630212) (Filer)

      11/22/23 4:49:04 PM ET
      $AVCO
      Building operators
      Real Estate
    • SEC Form 10-Q filed by Avalon GloboCare Corp.

      10-Q - Avalon GloboCare Corp. (0001630212) (Filer)

      11/14/23 4:30:53 PM ET
      $AVCO
      Building operators
      Real Estate
    • Avalon GloboCare Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Avalon GloboCare Corp. (0001630212) (Filer)

      11/9/23 4:30:46 PM ET
      $AVCO
      Building operators
      Real Estate

    $AVCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Avalon GloboCare Corp. (Amendment)

      SC 13D/A - Avalon GloboCare Corp. (0001630212) (Subject)

      1/24/24 8:35:42 PM ET
      $AVCO
      Building operators
      Real Estate

    $AVCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Tauzin W J

      4 - Avalon GloboCare Corp. (0001630212) (Issuer)

      3/9/23 11:12:55 AM ET
      $AVCO
      Building operators
      Real Estate
    • SEC Form 4 filed by Sanders Steven Andrew

      4 - Avalon GloboCare Corp. (0001630212) (Issuer)

      3/9/23 11:11:22 AM ET
      $AVCO
      Building operators
      Real Estate
    • SEC Form 4 filed by Stilley William B. Iii

      4 - Avalon GloboCare Corp. (0001630212) (Issuer)

      3/8/23 4:45:24 PM ET
      $AVCO
      Building operators
      Real Estate

    $AVCO
    Leadership Updates

    Live Leadership Updates

    See more
    • Avalon GloboCare Signs MOU to Form Strategic Partnership with Lu Daopei Hematology Institute to Develop Precision Companion Diagnostics for Cellular Therapy

      Goal of Partnership is to expand Avalon's R&D pipeline to include innovative companion diagnostics in association with the company's ongoing and future cellular immunotherapy clinical programs Appoints Dr. Hongxing Liu, a world-renowned expert in precision diagnostics for hematologic malignancies, to its Scientific and Clinical Advisory Board to further strengthen Avalon's companion diagnostics development capabilities FREEHOLD, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that the Company has signed a memorandum of understanding (MOU) with Lu Daopei Hematol

      5/18/22 9:00:00 AM ET
      $AVCO
      Building operators
      Real Estate
    • Siyata Mobile Appoints Peter Goldstein as Chairman and Adds Seasoned Public Company Executive Luisa Ingargiola to Board of Directors

      VANCOUVER, British Columbia, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Siyata Mobile Inc. (Nasdaq: SYTA, SYTAW) (“Siyata” or the “Company”), a leading global developer and provider of cellular communications solutions for enterprise customers, today announces the appointment of Peter Goldstein, currently a Siyata Board member, as the Chairman of its Board of Directors. In addition, Luisa Ingargiola, who has extensive experience on public company boards and in the capital markets, has been appointed to the Board of Directors effective as of the shareholders meeting on February 23, 2021. “Peter’s many years in working with emerging growth, publicly traded companies is paramount to our asking him to

      2/9/21 10:30:49 AM ET
      $SYTA
      $AVCO
      $SOLO
      $UAVS
      Telecommunications Equipment
      Telecommunications
      Building operators
      Real Estate